{"name":"Denali Therapeutics Inc.","slug":"denali-therapeutics","ticker":"DNLI","exchange":"NASDAQ","domain":"denalitherapeutics.com","description":"","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"","sector":"Biotech — Neuroscience","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":155000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"DNL126","genericName":"DNL126","slug":"dnl126","indication":"Other","status":"phase_1"},{"name":"DNL151","genericName":"DNL151","slug":"dnl151","indication":"Other","status":"phase_1"},{"name":"DNL628","genericName":"DNL628","slug":"dnl628","indication":"Other","status":"phase_1"},{"name":"DNL952","genericName":"DNL952","slug":"dnl952","indication":"Other","status":"phase_1"},{"name":"[14C]-DNL343","genericName":"[14C]-DNL343","slug":"14c-dnl343","indication":"Other","status":"phase_1"},{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","indication":"Other","status":"marketed"},{"name":"DNL201","genericName":"DNL201","slug":"dnl201","indication":"Other","status":"phase_1"},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DNL343","genericName":"DNL343","slug":"dnl343","indication":"Parkinson's disease (LRRK2-associated and idiopathic)","status":"phase_2"}]}],"pipeline":[{"name":"DNL126","genericName":"DNL126","slug":"dnl126","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DNL151","genericName":"DNL151","slug":"dnl151","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DNL628","genericName":"DNL628","slug":"dnl628","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DNL952","genericName":"DNL952","slug":"dnl952","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-DNL343","genericName":"[14C]-DNL343","slug":"14c-dnl343","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DNL201","genericName":"DNL201","slug":"dnl201","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DNL343","genericName":"DNL343","slug":"dnl343","phase":"phase_2","mechanism":"DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.","indications":["Parkinson's disease (LRRK2-associated and idiopathic)"],"catalyst":""},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":7,"marketed":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}